Valproate bismuth
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Valproate bismuth is a medication used to treat laryngitis.
- Generic Name
- Valproate bismuth
- DrugBank Accession Number
- DB13910
- Background
Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 638.598
Monoisotopic: 638.30201 - Chemical Formula
- C24H45BiO6
- Synonyms
- Bismuth dipropylacetate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Angina ••• ••• ••••• Treatment of Gingivostomatitis ••• ••• ••••• Treatment of Laryngitis ••• ••• ••••• Treatment of Pharyngitis ••• ••• ••••• Treatment of Sore throat ••• ••• ••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetophenazine Acetophenazine may increase the neurotoxic activities of Valproate bismuth. Alfentanil The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Valproate bismuth. Alimemazine Alimemazine may increase the neurotoxic activities of Valproate bismuth. Almotriptan The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Valproate bismuth. Amantadine The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Valproate bismuth. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Neo Laryngobis Enf Suppository 67.5 mg Rectal Lab Bio Chimique Inc.,Division Of Technilab Pharma Inc. 1950-12-31 1997-08-22 Canada Neo-laryngobis Suppository 135 mg Rectal TEVA Canada Limited 1950-12-31 Not applicable Canada
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as methyl-branched fatty acids. These are fatty acids with an acyl chain that has a methyl branch. Usually, they are saturated and contain only one or more methyl group. However, branches other than methyl may be present.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Fatty acids and conjugates
- Direct Parent
- Methyl-branched fatty acids
- Alternative Parents
- Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
- Substituents
- Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Hydrocarbon derivative / Methyl-branched fatty acid / Monocarboxylic acid or derivatives / Organic cation / Organic oxide
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 87PTX621FI
- CAS number
- 60364-28-5
- InChI Key
- YZDVVHSLIPLZLO-UHFFFAOYSA-K
- InChI
- InChI=1S/3C8H16O2.Bi/c3*1-3-5-7(6-4-2)8(9)10;/h3*7H,3-6H2,1-2H3,(H,9,10);/q;;;+3/p-3
- IUPAC Name
- bismuth(3+) tris(2-propylpentanoate)
- SMILES
- [Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O
References
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suppository Rectal 67.5 mg Suppository Rectal 135 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0716 mg/mL ALOGPS logP 6.2 ALOGPS logP 2.8 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 5.14 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 40.13 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 51.09 m3·mol-1 Chemaxon Polarizability 16.59 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 18, 2017 21:14 / Updated at May 21, 2024 16:36